For the first time in history, we now have an FDA-approved treatment for Parkinson’s disease Psychosis. It’s great news for longs and patients that have been suffering from grueling hallucinations associated with PDP.
While the FDA has asked for a black box warning due to increased risk of death associated with use in older people, the news is great for ACADIA Pharmaceuticals (ACAD). Nearly 40% of all Parkinson’s patients develop PDP along the way.
Now with treatment, they may not have to suffer much longer.
With approval in hand, the drug – Nuplazid – is expected to price near $13,500 per patient a year and reach a billion dollars in sales within four years.
What’s fascinating is this. Since recommending ACADIA at $1.05 and $1.24 in 2010, we’ve watched the stock soar to $51.99 for gains of 4,851% and 4,093%. It’s since pulled back but the gains are tough to ignore… with more upside likely for what some are calling a billion-dollar drug.
Congratulations to all longs that followed our advice. Job well done…